RBC Capital Downgrades Concordia Healthcare (CXRX) to Sector Perform
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/19/2026
- US stock futures steady after tech slump; investors focus on Middle East tensions
- U.S. Treasury doubles buyback operation size for long-dated bonds
- Marvell shares jump after giving Google warrants amid custom chip deal
- U.S. debt tops $40 trillion
- Nvidia credit risk gauge hits new peak as SoftBank readies record bond issue
- Marvell issues Google warrant tied to custom chip deal
- Tech selloff weighs down Wall Street as bond yields climb
- FOMC minutes from July 28-29th meeting
- Lowe's Cos. (LOW) Tops Q2 EPS by 17c, Misses on Revenue; Offers Fy27 Guidance
- US stock futures steady after tech slump; investors focus on Middle East tensions
Concordia International Announces Third Quarter 2016 Results
November 7, 2016 7:00 AM ESTOAKVILLE, ON, Nov. 7, 2016 /PRNewswire/ - Concordia International Corp. ("Concordia" or the "Company") (NASDAQ: CXRX) (TSX: CXR), an international specialty pharmaceutical company focused on generic and legacy pharmaceutical products and orphan drugs, today announced its financial and operational results for the three and nine months ended September 30, 2016. All financial references are in U.S. dollars unless otherwise noted.
Financial Results for the Third Quarter 2016
Revenue of $185.5 million, a decrease of 19.9% compared with the second quarter of 2016 or a 14.4% decrease... More